CSIRO designs new pharmaceutical products, advanced materials such as polymers and fabrics for injuries and uses computer-based technologies to improve treatment outcomes.
CSIRO Plant Industry conducts research to promote profitable and sustainable agrifood, fibre and horticultural industries, develop new plant products and improve natural resource management.
The question of how the food we eat influences the behaviour of our cells – including our genes – is the focus of a major international conference that starts today in Melbourne.
CSIRO has entered into an agreement with Adelaide-based biotech company, Oncaidia Ltd, to make the company’s new anti-cancer drug, Apomab®, suitable for human trials.
CSIRO is helping pharmaceutical companies with one of their most expensive, time-consuming tasks - identifying which chemical compounds to develop into new drugs.
Researchers are analysing components that make up certain foods to determine precisely what chemical and physical effects they have when eaten. With CSIRO's expertise we will be able to tailor our diets for better health and to avoid some diseases.
Working with internal and external partners in bioactive discovery for the pharmaceutical, biotechnology, animal health, crop protection and specialty chemical industries.
A CSIRO team - led by Dr Linfa Wang - has played a key role in uncovering a new reovirus that can cause a respiratory tract illness in humans. In this video, Dr Wang explains the significance of the discovery to CSIRO Communication Advisor, Ms Emma Wilkins. (6:00)
The goals and research of the Preventative Health Flagship and how the Preventative Health Flagship is developing preventative strategies to help fight chronic disease are introduced in this video. (6:00)
Dr Megan Fisher is acting Chief of CSIRO Molecular and Health Technologies, she has tertiary qualifications in science and business and an outstanding track record in strategic management, business development and technology commercialisation.
A list of RAFT (reverse addition fragmentation chain transfer) patents, their backgrounds, advantages of the invention and application areas. (7 pages)
The inaugural Australian Crystallisation course will be held during the 8th - 12th December, 2008, at Melbourne University with lectures at bio21 Victoria.
CSIRO’s IP is a platform technology for the rapid expansion of cells whilst maintaining phenotype. The technology will be useful for a wide range of cellular therapies and tissue engineering applications. (2 pages)
